AI and Organoids Revolutionize Drug Testing

Congress and the FDA are advocating for a shift from animal testing to advanced technologies in drug research. Researchers at Children’s Mercy Hospital have developed lab-grown ‘hearts’ from stem cells, which can help personalize treatment and reduce trial and error. These organoids, along with ‘organ-on-a-chip’ technology, offer more accurate drug testing, potentially saving the industry over $3 billion annually. The FDA Modernization 2.0 Act, signed by President Biden, allows for alternatives to animal testing, aiming to improve safety and reduce costs in drug development. This shift could transform the pharmaceutical landscape, enhancing efficiency and accuracy.